Biotechblog – Page 903 – Biotechnology business, policy, and more!

From PhD to Life

This is a guest post from Craig Stropkay. Craig is Director and Life Science Consultant at KOLgroups, LLC Reach for the […]

These are relative terms. If I license a product from you, I am in-licensing it and you are out-licensing it.

This is a guest post from Steve Kirsh. Steve is Founder + Managing Partner of Khameleon Group. When was the

This is a guest post from Avneet Heer, a student in the MS Biotechnology BioBusiness Track at Georgetown University. Do

How do biotech venture investments in public equities (known as VIPEs) perform? Do they outperform mutual funds and hedge funds?

How do biotech stocks behave during the first day of trading? How do they perform in the long-run period? What

After months of development and feedback from customers, DrugPatentWatch is proud to announce the availability of two new datasets: Bulk

This is a guest post from Mark D. Shtilerman1 and Joseph Eng Jr. Dr. Shtilerman is Senior Counsel at Deerfield

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post?

The latest on what the Trump presidency means for health care, hospitals, drug companies, and medical research. Tuesday, Nov. 15